{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:56:38Z","timestamp":1790402198120,"version":"4.1.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1097\/01.fpc.0000174787.92861.91","type":"journal-article","created":{"date-parts":[[2008,5,4]],"date-time":"2008-05-04T15:58:29Z","timestamp":1209916709000},"page":"779-786","source":"Crossref","is-referenced-by-count":87,"title":["CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population"],"prefix":"10.1097","volume":"15","author":[{"given":"Aurel C.","family":"Allabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Gala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Horsmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210212","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00008571-200204000-00010","article-title":"Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data","volume":"12","author":"Lee","year":"2002","journal-title":"Pharmacogenetics"},{"key":"R2-3-20210212","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0169-409X(02)00076-5","article-title":"CYP2C9 allelic variants: ethnic distribution and functional significance","volume":"54","author":"Xie","year":"2002","journal-title":"Adv Drug Del Rev"},{"key":"R3-3-20210212","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00228-002-0518-6","article-title":"Analysis of CYP2C9*5 in Caucasian, Oriental and Black-African populations","volume":"58","author":"Yasar","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"R4-3-20210212","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1046\/j.1365-2125.2003.01937.x","article-title":"Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations","volume":"56","author":"Allabi","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"R5-3-20210212","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.fpc.0000114749.08559.e4","article-title":"Identification of a novel variant CYP2C9 allele in Chinese","volume":"14","author":"Si","year":"2004","journal-title":"Pharmacogenetics"},{"key":"R6-3-20210212","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/01.fpc.0000114759.08559.51","article-title":"Discovery of new potentially defective alleles of human CYP2C9","volume":"14","author":"Blaisdell","year":"2004","journal-title":"Pharmacogenetics"},{"issue":"2","key":"R7-3-20210212","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2362.33.s2.6.x","article-title":"Clinical relevance of genetic polymorphisms in the human CYP2C9 gene","volume":"33","author":"Schwarz","year":"2003","journal-title":"Eur J Clin Invest"},{"key":"R8-3-20210212","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1124\/mol.60.2.382","article-title":"Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans","volume":"60","author":"Dickmann","year":"2001","journal-title":"Mol Pharmacol"},{"key":"R9-3-20210212","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.287.13.1690","article-title":"Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy","volume":"287","author":"Higashi","year":"2002","journal-title":"JAMA"},{"key":"R10-3-20210212","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00007691-200006000-00001","article-title":"Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis","volume":"22","author":"Ieiri","year":"2000","journal-title":"Ther Drug Monit"},{"key":"R11-3-20210212","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0021-9258(18)48462-1","article-title":"Subtrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences","volume":"267","author":"Gotoh","year":"1992","journal-title":"J Biol Chem"},{"key":"R12-3-20210212","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.clpt.2004.04.001","article-title":"Functional Impact of CYP2C9*5, *6, *8 and *11 in vivo among Black Africans","volume":"76","author":"Allabi","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"R13-3-20210212","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/00008571-200112000-00008","article-title":"Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin","volume":"11","author":"Kidd","year":"2001","journal-title":"Pharmacogenetics"},{"key":"R14-3-20210212","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1365-2125.1999.00012.x","article-title":"Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin","volume":"48","author":"Aynacioglu","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"R15-3-20210212","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/00008571-200110000-00005","article-title":"Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo","volume":"11","author":"Caraco","year":"2001","journal-title":"Pharmacogenetics"},{"key":"R16-3-20210212","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1046\/j.1365-2125.1996.00496.x","article-title":"Limited value of the urinary phenytoin metabolic ratio for the assessment of cytochrome P4502C9 activity in vivo","volume":"42","author":"Tassaneeyakul","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"R17-3-20210212","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1600-0773.1997.tb00006.x","article-title":"Phenytoin hydroxylation in a healthy Caucasian population: bimodal distribution of hydroxyphenytoin urinary excretion","volume":"81","author":"Horsmans","year":"1997","journal-title":"Pharmacol Toxicol"},{"key":"R18-3-20210212","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0009-9236(97)90031-X","article-title":"Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy","volume":"62","author":"Odani","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"R19-3-20210212","first-page":"615","article-title":"Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans","volume":"241","author":"Fritz","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"R20-3-20210212","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1365-2125.1997.00572.x","article-title":"Stereoselective 4\u2032-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese","volume":"43","author":"Ieiri","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"R21-3-20210212","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/j.1528-1157.1998.tb01330.x","article-title":"The effect of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics","volume":"39","author":"Mamiya","year":"1998","journal-title":"Epilepsia"},{"key":"R22-3-20210212","article-title":"Metabolic Drug Interactions","author":"Levy","year":"2000"},{"key":"R23-3-20210212","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/sj.tpj.6500025","article-title":"The predictive value of MDR1, CYP2C9, CYP2C19 polymorphisms for phenytoin plasma levels","volume":"1","author":"Kerb","year":"2001","journal-title":"Pharmacogenomics J"},{"key":"R24-3-20210212","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/00007691-200404000-00017","article-title":"Clinical aspects of the MDR1 (ABCB1) gene polymorphism","volume":"26","author":"Eichelbaum","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R25-3-20210212","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/00008571-200312000-00005","article-title":"Haplotype analysis of ABCB1\/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan","volume":"13","author":"Sai","year":"2003","journal-title":"Pharmacogenetics"},{"key":"R26-3-20210212","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/00008571-200208000-00002","article-title":"MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences","volume":"12","author":"Kim","year":"2002","journal-title":"Pharmacogenetics"},{"key":"R27-3-20210212","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00228-004-0879-0","article-title":"Single nucleotide polymorphisms of ABCB1 (MDR1) gene and distinct haplotype profile in West Black African Population","volume":"61","author":"Allabi","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"R28-3-20210212","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1067\/mcp.2001.117412","article-title":"Identification of functionally variant MDR1 alleles among European Americans and African Americans","volume":"70","author":"Kim","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"R29-3-20210212","first-page":"122","article-title":"The relationship between phenytoin pharmacokinetics and the CYP2C19 genotype in Japanese epileptic patients","volume":"21","author":"Watanabe","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"R30-3-20210212","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0009-9236(97)90027-8","article-title":"Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine","volume":"62","author":"Lown","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"R31-3-20210212","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","article-title":"Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo","volume":"97","author":"Hoffmeyer","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"R32-3-20210212","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/S0006-2952(99)00034-9","article-title":"Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese: difference in chiral preference of CYP2C9 and CYP2C19","volume":"57","author":"Yasumori","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"R33-3-20210212","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.0306-5251.2001.01499.x","article-title":"Clinical relevance of genetic polymorphisms in the human CYP2C subfamily","volume":"52","author":"Goldstein","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"R34-3-20210212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clpt.2004.08.009","article-title":"Clinical consequences of cytochrome P450 2C9 polymorphisms","volume":"77","author":"Kirchheiner","year":"2005","journal-title":"Clin Pharmacol Ther"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.fpc.0000174787.92861.91","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T01:48:41Z","timestamp":1738201721000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-200511000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1097\/01.fpc.0000174787.92861.91","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}